beraprost sodium mitigates renal interstitial fibrosis through repairing renal microvessels

Beraprost sodium (bps), as a prostacyclin analog, plays a significant role in various diseases based on its antiplatelet and vasodilation functions. however, its regulation and role in chronic kidney disease (ckd) still remain elusive. here, we determined whether bps could alleviate renal interstitial fibrosis, and improve the renal function and its therapeutic mechanism. in vitro, bps increased angiogenesis in the huvecs incubated with bps detected by tube formation assay and repair damaged endothelial cell–cell junctions induced by hypoxia. in vivo, mice were randomly assigned to a sham-operation group (sham), a unilateral ureteral obstruction group (uuo), and a bps intragastrical administration group (bps), and sacrificed at days 3 and 7 post-surgery (six in each group). in uuo model, tissue hypoxia, renal inflammation, oxidative stress, and fibrotic lesions were detected by q-pcr and western blot techniques and peritubular capillaries (ptcs) injury was detected by a novel technique of fluorescent microangiography (fma) and analyzed by matlab software. meanwhile, we identified cells undergoing endothelial cell-to-myofibroblast transition by the coexpression of endothelial cell (cd31) and myofibroblast (a-sma) markers in the obstructed kidney. in contrast, bps protected against interstitial fibrosis and substantially reduced the number of endothelial cell-to-myofibroblast transition cells. in conclusion, our data indicate the potent therapeutic of bps in mitigating fibrosis through repairing renal microvessels and suppressing endothelial-mesenchymal transition (endmt) progression after inhibiting inflammatory and oxidative stress effects.